Repligen tests secretin for MRI imaging of the pancreas

By Elaine Rigoli

Tampa, Fla., June 8 - Repligen Corp. has started a clinical trial to evaluate the use of RG1068, synthetic human secretin, as an agent to improve the detection of structural abnormalities of the pancreatic ducts during MRI imaging of the pancreas.

This is a multi-center, baseline-controlled, single-dose study in which 80 patients with a history of pancreatitis will receive a secretin-enhanced MRI and an unenhanced MRI of the pancreas.

This study will assess the sensitivity and specificity of secretin-enhanced MRI to improve the ability to detect pancreatic duct abnormalities relative to unenhanced MRI as well as the safety of secretin in combination with MRI, according to a news release.

Secretin is a natural gastrointestinal hormone involved in the process of digestion, which has been used for decades in the assessment of pancreatic exocrine function, the release said.

Based in Waltham, Mass., Repligen is a biopharmaceutical company that develops therapeutics for neuropsychiatric disorders and autoimmune diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.